FDA Missed Court Deadline for Mifepristone Review
The agency failed to provide a status update by October 7 on its ongoing review of the drug's safety protocols.
Updated on Oct. 7, 2026 in Law
Live Poll
Do you trust federal agencies to meet safety review deadlines without court intervention?
The FDA missed a court-ordered October 7, 2026, deadline to submit an update on its review of the abortion drug mifepristone. This delay follows ongoing legal challenges regarding the agency's removal of in-person dispensing requirements.
Why it matters
The review stems from promises by the Trump administration to conduct a thorough examination of the drug and agency protocols. Meanwhile, states argue that allowing mail-order access increases risks for women by bypassing direct medical supervision.
Federal guidance currently allows the use of mifepristone up to a gestational age of 70 days. A lawsuit filed by Texas and Florida remains paused until at least December 1, 2026, pending the completion of the FDA's mandated review.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating medications and public health protocols.
Reed O'Connor
He is a U.S. District Judge who granted a request to delay the lawsuit from Texas and Florida regarding drug access.
Marty Makary
He served as the FDA Commissioner before his departure in May 2026.
The details
The FDA originally adjusted four Risk Evaluation and Mitigation Strategy parameters for the drug in 2016 and later removed in-person requirements in 2023. While a Louisiana federal court previously paused a related challenge in April 2026, Judge Reed O'Connor recently granted a request to delay the Texas and Florida litigation until the agency concludes its assessment.
Timeline
In 2016, the FDA changed mifepristone dispensing protocol parameters.
The FDA allowed mifepristone to be sent through the mail in 2021.
The agency permanently removed the in-person requirement for the drug in 2023.
Louisiana filed a lawsuit challenging the mailing of abortion pills in October 2025.
The FDA failed to meet the October 7, 2026, deadline to provide a status update.
Political Context
The legal conflict centers on the FDA's authority to modify its Risk Evaluation and Mitigation Strategy protocols for abortion access. Opponents argue that these changes circumvent necessary medical safety standards, while federal officials maintain the current guidelines are supported by agency review.
The delay in the FDA's review prolongs legal uncertainty regarding how mifepristone is accessed and prescribed across different states. Residents in states like Texas face continued bans on the drug, while ongoing litigation remains a major factor in national access to medication.
The takeaway
The court-ordered delay underscores the deep legal division regarding federal regulatory authority over reproductive healthcare. As the December 1 deadline approaches, the future of mail-order access remains caught between agency administrative processes and federal court intervention.
Further reading
Learn more about federal litigation and regulatory proceedings in the Law section.
Source note: This article includes information reported by The Texan.
Live Poll
Do you trust federal agencies to meet safety review deadlines without court intervention?
